EXPLORATION PARK, Fla. (Space Florida PR) — Space Florida is proud to congratulate SpaceX for the successful docking of the CRS-10 mission with the ISS and to congratulate the 4 different experiments on board the Dragon capsule which were processed in the Space Life Sciences Lab (SLSL) in Exploration Park, Florida.
Those experiments were as follows:
Customer: CASIS/MERCK PI: Paul Reichert Protein crystal growth – pharmaceutical research (chemotherapy)
Customer: Edith Stein High School (agricultural high school in Ravensburg, Germany) PI: Maria Koch, Raphael Schilling and David Geray, German Students Vegetative propagation of plants on orbit
Customer: Intrinsyx Tech PI: John Freeman Designed to study enhanced plant growth of strong plants for astronauts on long duration Space missions
Customer: Space Tango PI: Twyman Clements
Another commercial opportunity to begin to utilize microgravity for application on Earth. The use of the SLSL for the processing of payloads for experiments and commercial operations will only grow as the flight cadence at the Cape Canaveral Spaceport increases in the years ahead.
“We’re excited to see the early investments by the State of Florida in payload processing for science and industry become a reality here at the Cape.” said Space Florida CEO Frank DiBello.
As the managers of the International Space Station (ISS) U.S. National Laboratory, The Center for Advancement of Science in Space (CASIS) works closely with NASA and ISS National Lab partners to maximize the impact of research and development on the ISS to directly benefit life on Earth. Inside this year’s report you will find many signals of progress, as well as, unique perspectives from diverse ISS National Lab users.
FY2015 highlights include:
Receiving significant outside investments in ISS National Lab programming, including an agreement from the National Science Foundation to commit $1.8 million toward an ISS National Lab sponsored program, a $550,000 grant from the Massachusetts Life Sciences Center for flight and education projects, and more than $250,000 from the Boeing Company to match a CASIS partnership with the Mass Challenge Accelerator program.
Growing non-traditional user demand—the ISS National Lab reached full capacity for allocated crew time for research that was both scientifically and economically reviewed for Earth benefit. These users included organizations like Merck, National Institutes of Health (NIH), iExpressGenes, RasLabs, Massachusetts Institutes of Technology (MIT), Novartis. Visidyne and University of Florida.
Conducting the first-ever mouse bone-density scans in orbit—improving the capability to study bone and muscle loss in rodent models. Studying rodent models in space has been identified by researchers as an accelerated pathway to better treatments for osteoporosis and muscle atrophy on Earth.
Mounting of the first commercial platform on the exterior of the ISS for commercial testing of research payloads, sensors, and electronic components in space—created and sponsored by the ISS National Lab commercial service provider NanoRacks, LLC.
KENNEDY SPACE CENTER, FL. (April 17, 2015) – The fifth series of payloads sponsored by the Center for the Advancement of Science in Space (CASIS) successfully berthed to the International Space Station (ISS) onboard Space Exploration Technologies Corporation’s (SpaceX) Dragon capsule. CASIS is tasked with managing and promoting research onboard the ISS U.S. National Laboratory.
Research onboard the SpaceX Dragon capsule includes a range of experiments sponsored by CASIS from the commercial and academic communities. Below is an overview of the major payloads sponsored by CASIS:
Osteo-4 (NIH Transitioned Payload) PI: Paola Divieti Pajevic, MD, Ph.D., Boston, MA, United States
Osteocytes and Mechanomechano-transduction (Osteo-4) studies the effects of microgravity on the function of osteocytes, which are the most common cells in bone. These cells reside within the mineralized bone and can sense mechanical forces, or the lack of them, but researchers do not know how. Osteo-4 allows scientists to analyze changes in the physical appearance and genetic expression of mouse bone cells in microgravity. (more…)
KENNEDY SPACE CENTER, FL., September 10, 2012 (CASIS PR) – The Center for the Advancement of Science in Space (CASIS) – manager of the International Space Station (ISS) U.S. National Laboratory – today announced that it is collaborating with global healthcare company Merck to conduct cutting-edge therapeutic research on board the ISS in 2013.
The ISS-based research will focus on therapeutic monoclonal antibodies (MABs), which are engineered proteins designed to bind to targets that cause disease, potentially allowing greater specificity than conventional therapies with fewer side effects.